 The purpose of this study is to assess the safety, pharmacokinetics, HCV RNA kinetics, and other viral characteristics after administration of two arms of MP-424 in combination with Peginterferon Alfa 2b PEG-IFN-a-2b and Ribavirin RBV to patients with chronic hepatitis C. 